Gyre Therapeutics, Inc.
GYRE
$7.64
$0.060.79%
NASDAQ
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 107.27M | 102.19M | 100.64M | 105.76M | 105.03M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 107.27M | 102.19M | 100.64M | 105.76M | 105.03M |
| Cost of Revenue | 4.85M | 4.18M | 3.80M | 3.88M | 3.96M |
| Gross Profit | 102.42M | 98.01M | 96.84M | 101.87M | 101.08M |
| SG&A Expenses | 77.79M | 75.66M | 73.48M | 73.62M | 77.82M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 95.23M | 92.85M | 90.21M | 89.53M | 94.66M |
| Operating Income | 12.03M | 9.34M | 10.43M | 16.23M | 10.38M |
| Income Before Tax | 15.27M | 11.58M | 15.37M | 23.22M | -77.83M |
| Income Tax Expenses | 3.46M | 2.84M | 3.68M | 5.32M | 5.82M |
| Earnings from Continuing Operations | 11.82 | 8.74 | 11.70 | 17.90 | -83.65 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -5.16M | -4.57M | -4.45M | -5.81M | -5.17M |
| Net Income | 6.65M | 4.17M | 7.25M | 12.09M | -88.82M |
| EBIT | 12.03M | 9.34M | 10.43M | 16.23M | 10.38M |
| EBITDA | 14.33M | 11.43M | 12.11M | 17.79M | 11.77M |
| EPS Basic | 0.07 | 0.05 | 0.08 | 0.14 | -1.25 |
| Normalized Basic EPS | 0.05 | 0.03 | 0.06 | 0.10 | -0.03 |
| EPS Diluted | 0.04 | 0.02 | 0.02 | 0.05 | -1.34 |
| Normalized Diluted EPS | 0.04 | 0.03 | 0.05 | 0.08 | -0.05 |
| Average Basic Shares Outstanding | 352.34M | 347.14M | 343.52M | 340.36M | 326.97M |
| Average Diluted Shares Outstanding | 394.60M | 393.27M | 392.77M | 393.39M | 380.00M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |